FR16C0017I2 - Composes pour l'inhibition enzymatique du proteasome - Google Patents

Composes pour l'inhibition enzymatique du proteasome

Info

Publication number
FR16C0017I2
FR16C0017I2 FR16C0017C FR16C0017C FR16C0017I2 FR 16C0017 I2 FR16C0017 I2 FR 16C0017I2 FR 16C0017 C FR16C0017 C FR 16C0017C FR 16C0017 C FR16C0017 C FR 16C0017C FR 16C0017 I2 FR16C0017 I2 FR 16C0017I2
Authority
FR
France
Prior art keywords
compounds
peptide
proteasome
based compounds
activities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0017C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyx Therapeutics Inc
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35502451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of FR16C0017I1 publication Critical patent/FR16C0017I1/fr
Application granted granted Critical
Publication of FR16C0017I2 publication Critical patent/FR16C0017I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
FR16C0017C 2004-08-06 2016-05-12 Composes pour l'inhibition enzymatique du proteasome Active FR16C0017I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59940104P 2004-08-06 2004-08-06
US61000104P 2004-09-14 2004-09-14
US11/106,879 US7232818B2 (en) 2004-04-15 2005-04-14 Compounds for enzyme inhibition
PCT/US2005/028246 WO2006017842A1 (en) 2004-08-06 2005-08-08 Compounds for proteasome enzyme inhibition

Publications (2)

Publication Number Publication Date
FR16C0017I1 FR16C0017I1 (ru) 2016-06-24
FR16C0017I2 true FR16C0017I2 (fr) 2016-08-26

Family

ID=35502451

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0017C Active FR16C0017I2 (fr) 2004-08-06 2016-05-12 Composes pour l'inhibition enzymatique du proteasome

Country Status (25)

Country Link
US (12) US7232818B2 (ru)
EP (4) EP3101026B1 (ru)
JP (2) JP4743720B2 (ru)
KR (3) KR20130080064A (ru)
CN (1) CN102286070B (ru)
AT (1) ATE496062T1 (ru)
AU (1) AU2005271232B2 (ru)
BR (2) BR122020008634B8 (ru)
CA (1) CA2589765C (ru)
CY (3) CY1116771T1 (ru)
DE (1) DE602005026019D1 (ru)
DK (2) DK3101026T3 (ru)
ES (2) ES2674277T3 (ru)
FR (1) FR16C0017I2 (ru)
HK (4) HK1103525A1 (ru)
HU (2) HUE038005T2 (ru)
IL (3) IL181127A (ru)
LT (2) LT3101026T (ru)
LU (1) LU93015I2 (ru)
NO (2) NO341015B1 (ru)
PL (2) PL3101026T3 (ru)
PT (2) PT3101026T (ru)
SG (2) SG155187A1 (ru)
SI (2) SI3101026T1 (ru)
WO (1) WO2006017842A1 (ru)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP1745064B1 (en) 2004-04-15 2011-01-05 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
PL2030981T3 (pl) 2004-05-10 2014-12-31 Onyx Therapeutics Inc Związki do enzymatycznej inhibicji proteasomu
US20050256324A1 (en) * 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
CN103230394B (zh) 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
US7737112B2 (en) * 2004-12-07 2010-06-15 Onyx Therapeutics, Inc. Composition for enzyme inhibition
PT2623113T (pt) 2005-11-09 2017-07-14 Onyx Therapeutics Inc Compostos para inibição de enzimas
JP5226679B2 (ja) 2006-06-19 2013-07-03 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
EP2040694A2 (en) * 2006-07-14 2009-04-01 VIB vzw Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
US7642369B2 (en) * 2006-09-12 2010-01-05 University Of Kentucky Research Foundation Epoxyketone-based immunoproteasome inhibitors
AU2013203566B2 (en) * 2007-10-04 2016-10-13 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2016231532B2 (en) * 2007-10-04 2018-05-10 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EA024437B1 (ru) * 2007-10-04 2016-09-30 Оникс Терапьютикс, Инк. Синтез кето-эпоксидов аминокислот
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
JP2011519975A (ja) 2008-05-12 2011-07-14 ネレアス ファーマシューティカルズ インコーポレイテッド プロテアソーム阻害剤としてのサリノスポラミド誘導体
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US20110009332A1 (en) * 2009-07-09 2011-01-13 Southwest Research Institute Therapeutic Treatment Of Wounds
GB0914883D0 (en) 2009-08-26 2009-09-30 Univ Belfast Compound
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011136905A2 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
WO2012135528A2 (en) 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
WO2013009923A1 (en) * 2011-07-13 2013-01-17 Creighton University Methods of promoting neuron growth
EP2776586B1 (en) 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013071142A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CN104204797B (zh) 2012-01-24 2017-05-31 米伦纽姆医药公司 治疗癌症的方法
EP2814849B8 (en) 2012-02-15 2020-03-04 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
US10159746B2 (en) 2012-05-08 2018-12-25 Onyx Therapeutics, Inc. Cyclodextrin complexation methods for formulating peptide proteasome inhibitors
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014015016A1 (en) 2012-07-18 2014-01-23 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
CA2881986A1 (en) * 2012-08-21 2014-02-27 Fluorinov Pharma Inc. Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
UA121095C2 (uk) 2012-10-22 2020-04-10 Сідекс Фармасьютікалс, Інк. Композиції алкілованого циклодекстрину і способи їх одержання і застосування
PT2968555T (pt) 2013-03-13 2020-07-14 Univ California Composições compreendendo anticorpos anti-cd38 e carfilzomib
DK2970225T3 (en) 2013-03-14 2018-09-24 Onyx Therapeutics Inc DIPEPTIDE AND TRIPEPTIDE AS EPOXY-KETONE PROTEASE INHIBITORS
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
US20160166632A1 (en) 2013-07-19 2016-06-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CN105518019A (zh) * 2013-09-06 2016-04-20 桑多斯股份公司 肽环氧基酮的合成
CA2922210A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
WO2015121769A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
CN103864889B (zh) * 2014-04-04 2017-01-11 重庆泰濠制药有限公司 环氧酮化合物、其制备方法及卡非佐米的制备方法
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
WO2016046843A1 (en) 2014-09-24 2016-03-31 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en) 2014-10-27 2016-05-06 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
CN104402973A (zh) * 2014-11-24 2015-03-11 重庆泰濠制药有限公司 一种卡非佐米无定型晶的制备方法
CN107548400A (zh) 2014-12-02 2018-01-05 费森尤斯卡比肿瘤学有限公司 卡非佐米的纯化方法
WO2016108204A1 (en) 2014-12-31 2016-07-07 Dr. Reddy's Laboratories Limited Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
WO2016170544A1 (en) * 2015-04-22 2016-10-27 Msn Laboratories Private Limited Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide
WO2016185450A1 (en) * 2015-05-21 2016-11-24 Laurus Labs Private Limited An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
CN106317188A (zh) * 2015-06-18 2017-01-11 重庆医药工业研究院有限责任公司 一种制备卡非佐米无定型物的方法
WO2017032487A1 (en) 2015-08-27 2017-03-02 Technische Universität München Proteasome inhibitor comprising a signal-emitting moiety
WO2017098532A1 (en) 2015-12-11 2017-06-15 Mylan Laboratories Limited Crystalline and amorphous forms of carfilzomib
TWI636052B (zh) * 2015-12-31 2018-09-21 中化合成生技股份有限公司 無定形卡非佐米(i)的製備方法
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
EP3494126A1 (en) 2016-08-02 2019-06-12 Synthon BV Process for making carfilzomib
MY204928A (en) 2016-08-05 2024-09-23 Amgen Inc Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof
WO2018051237A1 (en) 2016-09-14 2018-03-22 Fresenius Kabi Oncology Limited A process for purification of carfilzomib intermediate
EP3512602B1 (en) 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
EP3330260A1 (en) 2016-12-01 2018-06-06 Enantia, S.L. Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
WO2019053611A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
AU2018370019B2 (en) 2017-11-16 2024-10-24 Amgen Inc. Stable compositions of pegylated carfilzomib compounds
JP7422673B2 (ja) * 2017-12-08 2024-01-26 ニューロジーエックス エルエルシー アルツハイマー病についての同調させた細胞周期遺伝子発現試験および関連治療法
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US10689416B2 (en) 2017-12-30 2020-06-23 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
CA3043103C (en) * 2017-12-30 2021-02-09 Unity Biotechnology Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
EP3810131A1 (en) * 2018-06-22 2021-04-28 UCL Business Ltd Novel compounds
WO2021072212A1 (en) * 2019-10-11 2021-04-15 Mayo Foundation For Medical Education And Research Proteasome inhibitors
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024069240A2 (en) 2022-09-29 2024-04-04 Takeda Pharmaceutical Company Limited Cd38-binding fusion protein combination therapy
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
CN116768972A (zh) * 2023-06-25 2023-09-19 重庆药友制药有限责任公司 一种卡非佐米中间体的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569748A (en) 1896-10-20 Henry edmunds
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
US5071957A (en) * 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
US6099851A (en) * 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
EP1221962A2 (en) 1999-10-20 2002-07-17 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
EP1463719A2 (en) 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin and epoxomicin analogs and uses thereof
EP1745064B1 (en) * 2004-04-15 2011-01-05 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US20050256324A1 (en) * 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
PL2030981T3 (pl) 2004-05-10 2014-12-31 Onyx Therapeutics Inc Związki do enzymatycznej inhibicji proteasomu

Also Published As

Publication number Publication date
US7232818B2 (en) 2007-06-19
US20220267372A1 (en) 2022-08-25
IL181127A (en) 2013-03-24
EP2266999B1 (en) 2014-09-24
PL3101026T3 (pl) 2018-12-31
WO2006017842A1 (en) 2006-02-16
CY1116771T1 (el) 2016-08-31
PT1781688E (pt) 2011-04-05
EP3101026B1 (en) 2018-03-28
IL261892A (en) 2018-10-31
US7491704B2 (en) 2009-02-17
HK1231491A1 (zh) 2017-12-22
NO341015B1 (no) 2017-08-07
DE602005026019D1 (de) 2011-03-03
JP2011148805A (ja) 2011-08-04
BR122020008634B1 (pt) 2021-02-17
EP3101026A1 (en) 2016-12-07
EP2270026A3 (en) 2011-09-14
US7417042B2 (en) 2008-08-26
EP1781688A1 (en) 2007-05-09
IL181127A0 (en) 2007-07-04
IL261892B (en) 2019-12-31
US20140342977A1 (en) 2014-11-20
CY2016009I2 (el) 2016-08-31
US20160222057A1 (en) 2016-08-04
CY2016009I1 (el) 2016-08-31
US20150361134A1 (en) 2015-12-17
BRPI0514102B8 (pt) 2021-05-25
SG10201701794UA (en) 2017-04-27
SI3101026T1 (en) 2018-08-31
SI1781688T1 (sl) 2011-05-31
DK3101026T3 (en) 2018-06-18
KR20070047780A (ko) 2007-05-07
BRPI0514102B1 (pt) 2020-07-07
AU2005271232B2 (en) 2012-07-05
ATE496062T1 (de) 2011-02-15
CN102286070B (zh) 2014-12-10
JP5394423B2 (ja) 2014-01-22
US20200325172A1 (en) 2020-10-15
US20210179663A1 (en) 2021-06-17
US20050245435A1 (en) 2005-11-03
US20200071356A1 (en) 2020-03-05
EP2270026B1 (en) 2016-05-18
CA2589765A1 (en) 2006-02-16
EP1781688B1 (en) 2011-01-19
NO344397B1 (no) 2019-11-25
PT3101026T (pt) 2018-08-03
NO20070965L (no) 2007-04-16
LTPA2016010I1 (lt) 2016-04-25
LT3101026T (lt) 2018-07-10
PL1781688T3 (pl) 2011-06-30
CA2589765C (en) 2015-06-30
HUE038005T2 (hu) 2018-09-28
ES2674277T3 (es) 2018-06-28
JP2008509166A (ja) 2008-03-27
EP2266999A2 (en) 2010-12-29
LU93015I2 (fr) 2016-06-06
HUS1600014I1 (hu) 2016-05-30
NO20170381A1 (no) 2007-04-16
US20180170962A1 (en) 2018-06-21
LTC1781688I2 (lt) 2017-09-25
JP4743720B2 (ja) 2011-08-10
HK1152536A1 (en) 2012-03-02
IL221572A0 (en) 2012-10-31
ES2525248T3 (es) 2014-12-19
KR20130080064A (ko) 2013-07-11
IL221572B (en) 2018-10-31
EP2270026A2 (en) 2011-01-05
KR101544258B1 (ko) 2015-08-21
HK1103525A1 (en) 2007-12-21
KR101354280B1 (ko) 2014-01-23
CY1120677T1 (el) 2019-12-11
BRPI0514102A (pt) 2008-05-27
HK1152716A1 (zh) 2012-03-09
KR20120135355A (ko) 2012-12-12
AU2005271232A1 (en) 2006-02-16
BR122020008634B8 (pt) 2021-07-27
DK1781688T3 (da) 2011-03-14
US20070191284A1 (en) 2007-08-16
EP2266999A3 (en) 2011-09-14
CN102286070A (zh) 2011-12-21
SG155187A1 (en) 2009-09-30
FR16C0017I1 (ru) 2016-06-24
US20190211058A1 (en) 2019-07-11
US20060030533A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
FR16C0017I2 (fr) Composes pour l'inhibition enzymatique du proteasome
WO2005111008A3 (en) Compounds for enzyme inhibition
IL217210A0 (en) Compounds for proteasome enzyme inhibition
HK1121172A1 (en) Compounds for enzyme inhibition
WO2008140782A3 (en) Compounds for enzyme inhibition